November 21, 2016
Article
Findings from a recent phase II study showed the PD-L1 inhibitor durvalumab generated durable responses in bevacizumab-naïve patients with recurrent glioblastoma multiforme (GBM).
November 20, 2016
Article
The PD-1 inhibitor nivolumab was successfully combined with radiotherapy alone or concurrently with temozolomide for patients with newly-diagnosed glioblastoma multiforme in cohorts 1c and 1d from the phase I CheckMate-143 study.
November 20, 2016
Article
The IDH1 inhibitor AG-120 showed promising stable disease rates along with a few minor responses for patients with non-enhancing IDH1-mutated glioma across a variety of doses.
November 19, 2016
Article
Treatment with the combination of Optune and temozolomide improved overall survival by 4.8 months compared with temozolomide alone in patients with newly diagnosed glioblastoma multiforme.
November 19, 2016
Article
Treatment with the PD-1 inhibitor elicited a durable clinical benefit rate of 28% along with a manageable safety profile for patients with recurrent glioblastoma multiforme that expressed PD-L1 on ≥1% of cells.
November 19, 2016
Article
Treatment with the novel regimen of Toca 511 and Toca FC demonstrated a median overall survival of 13.6 months for patients with high-grade gliomas, representing a marked improvement over historical median survivals of 7.2 to 9.2 months.